Article

New treatment targets seasonal ocular allergic conjunctivitis

Fort Lauderdale, FL-Ophthalmic epinastine HCl is a new therapy for symptomatic relief of seasonal allergic conjunctivitis that is at least as effective and well tolerated as ketotifen fumarate (Zaditor, Novartis Pharmaceuticals, Duluth, GA), reported Stefano Bonini, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.

Fort Lauderdale, FL-Ophthalmic epinastine HCl is a new therapy for symptomatic relief of seasonal allergic conjunctivitis that is at least as effective and well tolerated as ketotifen fumarate (Zaditor, Novartis Pharmaceuticals, Duluth, GA), reported Stefano Bonini, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.

Epinastine HCl 0.05% ophthalmic solution is available in Europe as Relestat (Allergan, Irvine, CA) and in the United States as Elestat (Allergan and distributed by Inspire Pharmaceuticals, Durham, NC).

Epinastine, he explained, is a potent, non-sedating H1 antihistamine that also has affinity for the histamine H2 receptor. The drug, a mast cell stabilizer that prevents release of inflammatory mediators, has been shown to be efficacious and safe in conjunctival antigen challenge and environmental trials.

The study was conducted at sites in France and Italy. The patients in the control group were treated with ophthalmic ketotifen.

Fifty-one study patients received one drop per eye of epinastine twice daily for 14 days. Forty-eight control patients used ketotifen fumarate 0.025% ophthalmic solution.

Visual acuity was measured and slit-lamp examinations were performed at baseline, the day of treatment, and day 14. Ocular comfort was evaluated on the day of treatment, 30 minutes after the drops were instilled.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.